Drugs / COLULINTIDE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05380323 | May 2022 → Aug 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COLULINTIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068472 ↗ |
| Known as | LY3541105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05380323 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068472 ↗ |
| Route | Subcutaneous | “Single ascending doses of LY3541105 administered subcutaneously (SC).” NCT05380323 ↗ |